

# Andrea Cercek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4815577/publications.pdf>

Version: 2024-02-01

101  
papers

13,701  
citations

100601

38  
h-index

42259

96  
g-index

103  
all docs

103  
docs citations

103  
times ranked

20212  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic Artery Infusion Pump (HAIP) Therapy Versus Chemotherapy in the First-Line Setting for Patients with Unresectable Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 35-36.	0.7	2
2	MRI radiomics features of mesorectal fat can predict response to neoadjuvant chemoradiation therapy and tumor recurrence in patients with locally advanced rectal cancer. <i>European Radiology</i> , 2022, 32, 971-980.	2.3	34
3	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 125-137.	1.9	5
4	Molecular Characterization of Peritoneal Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2022, 17, 455-460.	0.5	24
5	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
6	Association of genomic profiles and survival in early onset and screening-age colorectal cancer patients with liver metastases resected over 15 years. <i>Journal of Surgical Oncology</i> , 2022, 125, 880-888.	0.8	4
7	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	2
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
9	Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment. <i>European Journal of Cancer</i> , 2022, 168, 25-33.	1.3	25
10	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2022, 157, 590.	2.2	25
11	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	0.8	292
12	PD-1 Blockade in Mismatch Repair-deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	13.9	588
13	Practical Considerations in Diagnosing and Managing Early-Onset GI Cancers. <i>Journal of Clinical Oncology</i> , 2022, 40, 2662-2680.	0.8	7
14	Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study. <i>Clinical Colorectal Cancer</i> , 2021, 20, e82-e95.	1.0	45
15	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	3.2	23
16	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 3685-3694.	0.7	3
17	Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin. <i>Annals of Surgical Oncology</i> , 2021, 28, 1109-1117.	0.7	5
18	Immunotherapy for the treatment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 760-774.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	0.8	34
20	In Defense of TNT: A Dynamite Strategy. <i>Journal of Clinical Oncology</i> , 2021, 39, 1185-1186.	0.8	3
21	Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?. <i>Hpb</i> , 2021, 23, 601-608.	0.1	3
22	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. <i>Clinical Cancer Research</i> , 2021, 27, 4101-4108.	3.2	24
23	A Coordinated Clinical Center for Young Onset Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 625-629.	1.9	8
24	Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2603-2611.	1.0	7
25	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	3.0	66
26	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	3.6	73
27	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	2.8	16
28	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	3.4	112
29	Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2020, 272, 352-356.	2.1	21
30	The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. <i>Hpb</i> , 2020, 22, 1271-1279.	0.1	8
31	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
32	Colorectal cancer statistics, 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 145-164.	157.7	3,302
33	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	3.2	62
34	Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—Reply. <i>JAMA Oncology</i> , 2020, 6, 935.	3.4	2
35	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 687-689.	0.6	33
36	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4123-TPS4123.	0.8	3

#	ARTICLE	IF	CITATIONS
37	ASO Author Reflections: Tumor Sidedness in CRS/IPC. <i>Annals of Surgical Oncology</i> , 2020, 27, 907-908.	0.7	0
38	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. <i>European Radiology</i> , 2019, 29, 458-467.	2.3	10
39	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. <i>Hpb</i> , 2019, 21, 1541-1551.	0.1	16
40	Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. <i>Annals of Surgical Oncology</i> , 2019, 26, 4599-4607.	0.7	19
41	Genomic stratification beyond Ras/Bâ€Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	1.3	8
42	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	15.2	320
43	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	1.4	16
44	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
45	Reducing the Morbidity of Rectal Cancer Treatment. <i>JAMA Oncology</i> , 2019, 5, 940.	3.4	1
46	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 167-174.	1.0	3
47	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	2.9	28
48	Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 8-18.	1.0	31
49	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	3.2	71
50	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	3.4	347
51	Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. <i>Annals of Surgical Oncology</i> , 2019, 26, 118-124.	0.7	18
52	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	1.0	21
53	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. <i>European Radiology</i> , 2019, 29, 1733-1742.	2.3	9
54	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018, 4, 309.	3.4	146

#	ARTICLE	IF	CITATIONS
55	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	7.7	589
56	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	3.4	404
57	Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. <i>Journal of Surgical Oncology</i> , 2018, 117, 634-643.	0.8	67
58	HER2: An emerging target in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 560-571.	1.0	67
59	Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3520-3520.	0.8	3
60	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. <i>Journal of the American College of Surgeons</i> , 2017, 224, 906-916.	0.2	56
61	Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 3, 163-173.	2.3	220
62	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
63	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 4753-4760.	3.2	56
64	A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. <i>Current Treatment Options in Oncology</i> , 2017, 18, 42.	1.3	7
65	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1087-1095.	0.4	44
66	Robotic hepatic arterial infusion pump placement. <i>Hpb</i> , 2017, 19, 429-435.	0.1	19
67	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.4	58
68	A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapson 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 577-579.	0.6	13
69	The care of the colorectal cancer survivor. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 26-33.	1.0	5
70	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	2.0	43
71	Clinicopathologic Features of Young Onset Colorectal Cancer Patients: Results From a Large Cohort at a Single Cancer Center. <i>American Journal of Gastroenterology</i> , 2017, 112, S108.	0.2	1
72	Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1938-1944.	0.8	112

#	ARTICLE	IF	CITATIONS
73	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. <i>Oncotarget</i> , 2017, 8, 42487-42494.	0.8	10
74	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	0.8	204
75	Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m <sup>2</sup> /min. <i>Journal of Oncology Practice</i> , 2016, 12, e548-e553.	2.5	4
76	Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. <i>Journal of Surgical Oncology</i> , 2016, 114, 655-663.	0.8	43
77	Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. <i>Journal of Surgical Oncology</i> , 2016, 113, 477-484.	0.8	67
78	Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3539-3539.	0.8	51
79	Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. <i>Hpb</i> , 2015, 17, 644-650.	0.1	5
80	Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal Cancer. <i>Annals of Surgery</i> , 2015, 261, 353-360.	2.1	171
81	Treatment of Peritoneal Carcinomatosis of Colorectal Origin. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e208-e211.	1.8	4
82	Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1313-1320.	3.2	240
83	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014, 15, 454.	3.8	296
84	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 513-518.	0.8	375
85	Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab. <i>Annals of Surgical Oncology</i> , 2014, 21, 479-486.	0.7	39
86	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 207-212.	1.0	37
87	False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 907-913.	2.3	81
88	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 513-519.	2.3	186
89	Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 597-597.	0.8	1
90	False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 403-403.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies.. Journal of Clinical Oncology, 2014, 32, 3623-3623.	0.8	0
92	Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?. Current Colorectal Cancer Reports, 2013, 9, 126-129.	1.0	0
93	Incidence of Chemotherapy-Induced Amenorrhea in Premenopausal Women Treated With Adjuvant FOLFOX for Colorectal Cancer. Clinical Colorectal Cancer, 2013, 12, 163-167.	1.0	31
94	Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases.. Journal of Clinical Oncology, 2013, 31, 3609-3609.	0.8	1
95	Chemotherapy first, followed by chemoradiation (CRT) and then surgery, in the management of locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2013, 31, 3605-3605.	0.8	0
96	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	0.8	254
97	Conversion to complete surgical treatment using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 472-472.	0.8	0
98	BEYOND KRAS: Other Markers and Potential Treatment Strategies for KRAS Mutant and Wild-type Patients. Current Treatment Options in Oncology, 2011, 12, 126-135.	1.3	3
99	Evolving Treatment of Advanced Colorectal Cancer. Current Oncology Reports, 2010, 12, 153-159.	1.8	16
100	First-Line Treatment of Patients with Metastatic Colorectal Cancer: An Overview of Recent Data on Chemotherapy plus Targeted Agents. Clinical Colorectal Cancer, 2008, 7, S47-S51.	1.0	6
101	Hepatic Arterial Infusion Pumps. , 0, , 121-121.		2